| Date Filed | Type | Description |
| 08/09/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/09/2023 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data |
| 08/02/2023 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data |
| 06/01/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 05/25/2023 |
8-K
| Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits Interactive Data |
| 05/11/2023 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data |
| 05/11/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/09/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 05/03/2023 |
8-K
| Quarterly results |
| 04/28/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 04/21/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 03/17/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 03/17/2023 |
S-3
| Form S-3 - Registration statement under Securities Act of 1933: |
| 03/13/2023 |
4/A
| Zanganeh Mahkam (Co-CEO & President) has filed a Form 4 on Summit Therapeutics Inc.|
Txns:
| Bought 16,778,415 shares
@ $1.05, valued at
$17.6M
Bought 6,748,629 shares
@ $1.05, valued at
$7.1M
|
|
| 03/13/2023 |
SC 13D/A
| Zanganeh Mahkam reports a 5.3% stake in Summit Therapeutics Inc. |
| 03/09/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/09/2023 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data |
| 03/08/2023 |
4
| Zanganeh Mahkam (Co-CEO) has filed a Form 4 on Summit Therapeutics Inc.|
Txns:
| Bought 15,973,743 shares
@ $1.05, valued at
$16.8M
Bought 804,672 shares
@ $1.05, valued at
$844.9k
Bought 6,748,629 shares
@ $1.05, valued at
$7.1M
|
|
| 03/08/2023 |
4
| Dhingra Ankur (CFO) has filed a Form 4 on Summit Therapeutics Inc.|
Txns:
| Bought 196,362 shares
@ $1.05, valued at
$206.2k
|
|
| 03/08/2023 |
4/A
| Dhingra Ankur (CFO) has filed a Form 4 on Summit Therapeutics Inc.|
Txns:
| Bought 13,027 shares
@ $0.97, valued at
$12.6k
Bought 24,658 shares
@ $0.97, valued at
$23.9k
|
|
| 03/08/2023 |
4
| DUGGAN ROBERT W (CEO) has filed a Form 4 on Summit Therapeutics Inc.|
Txns:
| Bought 376,489,880 shares
@ $1.05, valued at
$395.3M
|
|
| 02/23/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 02/14/2023 |
SC 13G/A
| Polar Capital Holdings Plc reports a 0% stake in Summit Therapeutics Inc. |
| 02/07/2023 |
424B4
| Form 424B4 - Prospectus [Rule 424(b)(4)]: |
| 01/30/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 01/27/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 01/26/2023 |
3
| Xia Yu (Director) has filed a Form 3 on Summit Therapeutics Inc. |
| 01/20/2023 |
S-3/A
| Form S-3/A - Registration statement under Securities Act of 1933: [Amend] |
| 01/09/2023 |
8-K
| Results of Operations and Financial Condition, Submission of Matters to a Vote of Security Holders, Regulation FD Disclosure,... |
| 01/05/2023 |
4
| Booth Robert F. (Director) has filed a Form 4 on Summit Therapeutics Inc.|
Txns:
| Granted 35,000 options to buy
@ $5, valued at
$175k
Granted 32,700 options to buy
@ $5, valued at
$163.5k
|
|
| 01/05/2023 |
4
| Cesano Alessandra (Director) has filed a Form 4 on Summit Therapeutics Inc.|
Txns:
| Granted 35,000 options to buy
@ $5, valued at
$175k
Granted 16,350 options to buy
@ $5, valued at
$81.8k
|
|
| 01/05/2023 |
4
| Mahatme Ujwala (Director) has filed a Form 4 on Summit Therapeutics Inc.|
Txns:
| Granted 35,000 options to buy
@ $5, valued at
$175k
Granted 40,500 options to buy
@ $5, valued at
$202.5k
|
|
| 01/05/2023 |
4
| Clark Kenneth A (Director) has filed a Form 4 on Summit Therapeutics Inc.|
Txns:
| Granted 35,000 options to buy
@ $5, valued at
$175k
Granted 44,400 options to buy
@ $5, valued at
$222k
|
|
| 01/05/2023 |
4
| Soni Manmeet Singh (Director) has filed a Form 4 on Summit Therapeutics Inc.|
Txns:
| Granted 35,000 options to buy
@ $5, valued at
$175k
|
|
|